FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Imec, the world-leading research and innovation hub in nano-electronics and digital technologies, is granting its Lifetime of Innovation Award to Dr. Kinam Kim, President and CEO of Semiconductor Business at Samsung Electronics. The selection recognizes Dr. Kim’s leadership and strategic vision, as well as his undeniable impact in the semiconductor industries. read more
Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial year 2016. read more
First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund operations until mid-2019. read more
This Saturday, Biocartis is present at the investor event VFB Happening, organized by the Flemish Federation of Investors, on the topic Technology. Our CEO Hilde Windels will speak about our continuous technological innovations, and our commitment at Biocartis to give all patients access to treatments with the best possible health outcome, through faster, easier and more accurate (cancer) diagnostics. read more
B55α is one of the regulatory subunits of the PP2A phosphatase. This phosphatases has been associated to the control of many biological functions but the multiplicity of complexes that can be formed by the combination of different subunits renders this protein hard in its understanding. The Massimiliano Mazzone group (VIB-KU Leuven) has recently demonstrated that PP2A/B55α promotes the growth of colorectal cancer, by dephosphorylating PHD2 and modifying its enzymatic properties. PHD2 is a member of a family of enzymes crucial for the cellular response to hypoxia. read more
Novosanis today announced that it signed an agreement with MDxHealth to supply UrNCollect™, a customized version of the Company’s patented urine collection device called Colli-Pee™. The medical device facilitates accurate sample collection for urine-based tests. read more
Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with novel potentiator GLPG3067 for cystic fibrosis (CF) in a Phase 1 study. Galapagos is to receive a $7.5 million milestone payment from its collaboration partner AbbVie for this achievement. read more
MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Lab21 Clinical Laboratory's urology clients in the United Kingdom. read more
argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. read more
Led by professor Ludo Van Den Bosch (VIB-KU Leuven), scientists from Belgium, the UK and the US have identified new processes that form protein “clumps” that are characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). How these proteins, which can bind RNA in normal cells, stick together has remained elusive until recently, when scientists demonstrated that they demix from the watery substance inside cells, much like oil separates from water. Prof. Van Den Bosch’s team sheds light onto the molecular interactions behind the process in patients with defects in the C9orf72 gene. Their results are featured on the cover of the leading journal Molecular Cell. read more